Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.10 USD
Change Today -0.054 / -2.51%
Volume 59.0K
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 10:09 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Open
$2.15
Previous Close
$2.15
Day High
$2.20
Day Low
$2.05
52 Week High
04/1/14 - $12.09
52 Week Low
02/4/15 - $1.92
Market Cap
47.5M
Average Volume 10 Days
177.2K
EPS TTM
$-1.56
Shares Outstanding
22.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOGENEX PHARMACEUTICAL INC (OGXI)

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

35 Employees
Last Reported Date: 03/26/15

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $503.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $403.1K
Compensation as of Fiscal Year 2013.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

OncoGenex Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue for the fourth quarter and year ended December 31, 2014 was $5.7 million and $27.1 million, respectively. Net loss was $5.7 million. For the year, the company reported revenue of $8.6 million and $29.9 million, respectively, in the same periods in 2013. Net loss was $26.2 million.

OncoGenex Pharmaceuticals, Inc. Proposes Amendment to Certificate of Incorporation

OncoGenex Pharmaceuticals, Inc. announced that at the AGM to be held on May 21, 2015, the shareholders will consider amendment to certificate of incorporation to increase authorized shares of common stock from 50,000,000 to 75,000,000.

OncoGenex Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 26, 2015

OncoGenex Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.10 USD -0.054

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit www.oncogenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.